Psychiatric Rx May Protect Against Cartilage Decline in Osteoarthritis

This article originally appeared here.
Psychiatric Rx May Protect Against Cartilage Decline in Osteoarthritis
Psychiatric Rx May Protect Against Cartilage Decline in Osteoarthritis

(HealthDay News) — Lithium reduces catabolic events in interleukin-1 β (IL-1β)-treated human articular chondrocytes and protects against cartilage degradation in IL-1β-treated mouse knee joints, according to a study published in the May issue of Arthritis & Rheumatology.

Takeshi Minashima, PhD, from New York University, and colleagues treated human articular chondrocytes with lithium chloride (LiCl) and IL-1β. Real-time polymerase chain reaction then determined expression levels of catabolic genes. Additionally, the activation of NF-KB was determined using luciferase reporter assays. Immunoblot analysis of total cell lysates determined the activities of MAPKs and the STAT-2 signaling pathway.

The researchers found that LiCl treatment resulted in decreased catabolic marker messenger RNA levels and activation of NF-KB, p38 MAPK, and STAT-3 signaling in IL-1β-treated articular chondrocytes. LiCl also directly inhibited IL-6-stimulated activation of STAT-3 signaling. Eight weeks after osteoarthritis induction surgery, the severity of cartilage destruction in LiCl-treated mouse knee joints or in LiCl-treated mouse femoral head explants after IL-1β treatment were markedly reduced versus in vehicle-treated joints or explants.

"LiCl reduced catabolic events in IL-1β-treated human articular chondrocytes and attenuated the severity of cartilage destruction in IL-1β-treated mouse femoral head explants and in the knee joints of mice with surgically induced OA," the authors write.

Abstract
Full Text (subscription or payment may be required)

Loading links....